The FTC sued Kushly for its misleading marketing materials on CBD’s miracle cure for cancer and Alzhemier’s.

In the fall of 2020, the Federal Trade Commission (FTC) launched a legal complaint that sent shockwaves through the then burgeoning CBD marketplace. The villain was a corporation called Kushly Industries LLC which allegedly made sweeping—yet utterly unsubstantiated—health and disease-treatment claims about their CBD products. From insomnia and PTSD to cancer and Alzheimer’s, Kushly’s promotional materials claimed time and again that their product could address numerous medical conditions, often pointing to non-existent or misrepresented “scientific research” to justify their statements. The FTC, however, found the evidence lacking. Taken together, these allegations paint a damning portrait: a corporation leveraging regulatory gaps, consumer trust, and the allure of an emerging health trend to make grand promises unsupported by credible scientific studies.

But Kushly’s story transcends the four corners of a single complaint. Instead, it illuminates a pattern of corporate misconduct that thrives in an environment shaped by neoliberal capitalism, where deregulation, corporate lobbying, and profit-maximization often push corporations to behave in ways that endanger public health, flout consumer interests, and deepen wealth inequality. This article serves as an investigative deep-dive into these allegations—an examination of the corporate strategies, systemic pressures, and regulatory blind spots that can allow such schemes to flourish.

We will, in what follows, excavate the key allegations from the FTC’s complaint and situate them within the larger context of global corporate accountability. Along the way, we will draw parallels to other industries that have faced legal scrutiny for deceptive marketing, from Big Tobacco to certain supplement manufacturers. We will also explore broader themes of regulatory capture and the profit motives that drive corporations to overreach, risking the health and economic well-being of workers and communities around the globe. By the end, our hope is that readers will not merely see the Kushly case as a one-off instance of corporate overstatement but rather as a symptom of a deeper malady that emerges when short-term financial gain trumps corporate social responsibility.

Corporate Intent Exposed

The FTC complaint against Kushly Industries LLC lays out a litany of allegations suggesting that the company made unproven medical claims about its CBD offerings. According to the FTC, Kushly and its top executive engaged in a methodical strategy to promote the brand’s CBD tinctures, gummies, lotions, toothpicks, and other products with statements that they could treat a staggering array of ailments: anxiety, depression, eczema, arthritis, multiple sclerosis, certain forms of cancer, Parkinson’s disease, Alzheimer’s disease, and more. These claims appeared on the company’s official website, in social media posts, blog articles, and even through direct marketing pitches.

The complaint underscores that the company’s marketing pointed to “studies” or “scientific evidence” that proved the efficacy of its CBD products. Yet the FTC found no credible, peer-reviewed research to validate these extraordinary claims. Instead, Kushly’s representations appeared to rely on cherry-picked anecdotes, misinterpretations of early-stage scientific data, or in some cases, pure invention. When challenged to provide real substantiation—namely, randomized clinical trials—the complaint alleges that Kushly came up short.

These findings imply more than mere laziness in marketing. They suggest a willful intent to mislead consumers in pursuit of higher sales—a hallmark of corporate misconduct. While it’s not unusual for supplement or health product companies to tout the potential benefits of CBD or other natural compounds, Kushly’s advertising verged on the extreme. Allegedly claiming to prevent the development of cancer, reduce blood pressure, treat neurological disorders, and reverse everything from anxiety to insomnia crosses the line from legitimate scientific curiosity into territory well outside established medical consensus. This leap from uncertain, preliminary science to definitive health solutions is precisely the kind of corporate overreach that fosters distrust in emerging fields and can undermine legitimate avenues of research.

Moreover, the story told by the complaint goes beyond inflated claims. It reveals a strategy that is common among corporations operating in loosely regulated or newly emerging markets: push the boundaries of permissible claims, gather customers by any means necessary, and worry about regulatory actions only if or when they arrive. Often, the potential fine or settlement is dwarfed by the profits garnered from quickly scaling a brand in a hot new market—in this case, the CBD sector. This “act first, apologize later” mindset thrives in neoliberal capitalist frameworks where the impetus is on rapid growth and short-term profit, rather than long-term public wellbeing.

The Corporations Get Away With It

One of the most alarming revelations of the Kushly saga is the ease with which such alleged misrepresentations can slip through the cracks of regulatory oversight—at least for a time. The complaint makes it abundantly clear that Kushly’s conduct was ongoing until the FTC stepped in. But stepping in does not necessarily translate into comprehensive consumer redress. The settlement in such cases often requires the company to issue refunds, correct misleading advertising, or pay a monetary penalty. Yet by the time these corrective actions occur, a great deal of harm may already have been done. Consumers might have spent hundreds or thousands of dollars on products they believed would cure or alleviate serious health conditions. Some might have forgone more proven treatments in favor of CBD items. In extreme scenarios, unsubstantiated claims about curing cancer or mitigating Alzheimer’s disease can directly endanger public health if they dissuade individuals from seeking legitimate medical care.

Meanwhile, from a purely corporate perspective, such legal cases may seem like little more than the “cost of doing business,” especially if the initial profits dwarf the eventual settlement. In the short term, corporations exploiting new, loosely regulated markets can rack up substantial earnings. By the time regulators intervene, these corporations can choose to settle, pay a fine, and rebrand or pivot to a slightly different marketing campaign—often retaining a chunk of ill-gotten gains in the process.

Even though the FTC is far from toothless, the pace of legal investigations can be slow. Often, regulators must comb through vast troves of marketing materials, online advertisements, and blog posts, carefully assessing the veracity of each health claim. Corporations know that government agencies operate with finite resources, so it is often in a firm’s strategic interest to push unverified claims for as long as possible. Ultimately, even if a lawsuit or complaint emerges, many companies bank on the likelihood that a settlement will not exceed the returns gained from aggressive marketing campaigns.

This pattern is not limited to the CBD industry. It repeats in pharmaceuticals, dietary supplements, food products, even financial services. Wherever the regulatory net is not taut, unscrupulous players can identify a lucrative gap. Over time, these repeat incidents erode public trust not only in specific companies but also in the broader notion of corporate accountability. For many consumers, watching alleged deception go largely unpunished except by manageable financial penalties reinforces the narrative that big corporations receive kid-glove treatment under neoliberal capitalism. And from the vantage point of public health, such outcomes risk putting vulnerable populations—like individuals with chronic illnesses or the elderly—at the greatest risk of harm.

The Cost of Doing Business

Baked into every corporate decision is a cost-benefit analysis—an assessment of what can be gained versus what must be risked. For Kushly, the chance to aggressively market CBD products with bold, disease-curing statements likely generated excitement, brand recognition, and substantial revenue in a blossoming market. Indeed, CBD sales across the United States have been skyrocketing over the past decade, fueled by public enthusiasm for alternatives to prescription medications, as well as the wider legalization of cannabis-derived products. The financial carrot dangled in front of corporations operating in this space can be enormous.

Meanwhile, the stick—namely, regulatory or legal pushback—has proven relatively weak or slow to materialize. Even if a corporation faces an FTC complaint, as Kushly eventually did, the fines and constraints might come too late to quell the surge of profits made during the brand’s initial ascendancy. In some cases, the fine is dwarfed by the profits. If the financial penalty fails to match the seriousness of the alleged misconduct, it signals to other market players that such tactics can be worth the gamble. The end result? A business culture where short-term profit trumps corporate ethics, fueling further corporate greed and leaving consumers to sort out the truth from a barrage of marketing hype.

If we zoom out to the broader context of late-stage capitalism, the phenomenon is hardly surprising. The structure of corporate governance often rewards CEOs and executives for delivering quarterly returns. Shareholders typically demand profit growth above all else. This environment fosters an incentive to exploit novel product markets—like CBD—before regulators even have time to craft robust policies. By the time rule-making catches up, entire corporate empires can rise and fall, leaving a wake of misinformation and public health crises.

But it is not only the direct consumers of these products who pay a price. The trickle-down effects—like diminished trust in regulatory bodies, questionable job security for employees in companies that suddenly must drastically change course, and local economic instability—compound the problems. Indeed, when a brand’s fortunes soar on the strength of unverified claims, local communities initially benefit from job creation and tax revenues. Should that company collapse under regulatory scrutiny or consumer backlash, layoffs and financial turmoil can follow.

Systemic Failures

The Kushly example underscores a broader, more systemic problem under neoliberal capitalism: regulatory capture and weakened enforcement mechanisms. Regulatory agencies, such as the FTC, often find themselves stretched thin. They are mandated to protect consumers, yet they must do so under the constraints of limited budgets and political forces that shape their mission and scope. Meanwhile, industry lobbyists and corporate interests wield outsized influence in shaping the legislative environment. Whether it’s the banking industry during the mortgage crisis or the dietary supplement sector grappling with spurious claims, the pattern is consistent: when regulations are watered down and oversight is starved of resources, corporate misconduct proliferates.

In the specific case of the CBD industry, federal agencies have struggled to keep pace with the product explosion. The Food and Drug Administration (FDA) has only gradually begun clarifying how CBD products should be regulated, leaving companies uncertain as to what they can legally claim about health benefits. In the vacuum of robust guidance, unscrupulous companies can—and do—make bold marketing claims that push boundaries. As a result, a dizzying array of “miracle cures” flood the market, from gummies that purport to vanquish depression to lotions that promise to banish eczema overnight.

Though the FTC and FDA have tried to crack down on such unsubstantiated claims—often through warning letters or the occasional high-profile complaint—this approach is reactionary. By the time a case goes to court, countless bottles and tubs of product have likely already been sold, and many consumers may have pinned their hopes on these unverified cures. Beyond the direct losses in consumer dollars, there’s the psychological harm and erosion of consumer confidence in legitimate health research.

Systemically, these conditions of minimal oversight form the perfect breeding ground for what can be described as “predatory capitalism.” Under such a system, businesses that manipulate public fears or exploit emerging consumer trends can experience explosive growth. They often do so by sowing confusion, misrepresenting research, or fueling conspiracies about “hidden cures” that the medical establishment supposedly wants to keep secret. While these tactics are ethically dubious, they can, in some market conditions, yield significant short-term success—further illustrating how existing systems can fail to protect public health.

This Pattern of Predation Is a Feature, Not a Bug

When analyzing allegations like those against Kushly, it is tempting to see them as isolated incidents of corporate bad apples. But a deeper reading suggests that the problem is structural—part and parcel of a profit-driven system that is, at best, ambivalent about public well-being. Far from being a glitch, it often seems that predatory corporate strategies are a deliberate feature of how business is conducted under neoliberal capitalism.

Look closely at how companies approach new product categories. Under typical circumstances, responsible corporations commission thorough scientific studies before making any health-related claims. They might partner with universities, sponsor medical trials, or consult with scientific experts. Those steps are expensive, time-consuming, and can delay a product launch—a clear disadvantage in a competitive market. In contrast, a more opportunistic company might skip that rigorous phase, substituting marketing bravado for actual evidence, and leapfrog into the public’s consciousness. By the time regulators intervene, the unscrupulous player can carve out a market niche.

Such tactics benefit from widespread consumer anxieties—about health, the high costs of medical care, and the failings of mainstream medicine. Neoliberal economies, with their emphasis on privatizing public services and minimizing social welfare, often generate the perfect conditions for pseudoscientific “miracle solutions” to flourish. This dynamic is exacerbated by wealth disparity, as many individuals who cannot afford traditional healthcare may leap at promises of a cheaper, more natural alternative.

The persistent underfunding of regulatory bodies is not accidental. Rather, it reflects deep-seated priorities: trusting the free market to police itself and focusing on short-term gains over long-term societal benefits. This environment fosters a cycle in which companies like Kushly can flourish, even if their rise is built on shaky or outright false marketing. The demise of one such company does little to dissuade the next wave of opportunists, as the fundamental incentives—and structural loopholes—remain in place.

The PR Playbook of Damage Control

In the wake of public scrutiny or an official complaint, many corporations follow a well-trodden PR playbook. Step one is often denial or downplaying the severity of the allegations: “We are confident our statements have been misunderstood” or “This is all a matter of misinterpretation.” Step two is to hedge liability by distancing the company from direct wrongdoing—sometimes attributing statements to “independent affiliates” or “third-party content.” Step three is to swiftly settle or comply with administrative orders, pay a penalty, and pivot marketing language just enough to appear compliant, all while maintaining as many of the original profit-generating features as possible.

The allegations against Kushly fit neatly into that larger narrative. According to the FTC, Kushly flooded its website and social media with promotional copy claiming to treat everything from anxiety to Parkinson’s disease. After the FTC intervened, Kushly’s online presence was adjusted to remove or alter the disputed content. If you search for their materials now, many of the most aggressive statements have vanished. Meanwhile, the settlement with the FTC requires disclaimers and scientifically accurate marketing. While that may suggest progress, these incremental changes do little to address the damage done to consumer trust or the structural environment that fosters such tactics.

And from a PR perspective, once a settlement is in place, many corporations try to spin it as an endorsement of their legitimacy: “We have resolved any misunderstandings and remain committed to consumer well-being.” This approach helps salvage brand reputation, maintain consumer goodwill, and assure stakeholders that profits can still be maintained. But it also rings hollow to those who read the fine print of the settlement, which typically reveals no admission of guilt but a pledge to refrain from repeating the dubious claims. That vow only begs the question: If these claims had been legitimate, why retract them?

Corporate Power vs. Public Interest

The disheartening reality is that corporations accused of misconduct often possess resources and organizational power far beyond those of the regulators or communities they harm. By hiring high-priced legal teams and leveraging their capital, they can delay or weaken enforcement actions. They can also lobby for legislation that further dilutes consumer protections. In the realm of public health, the results can be tragic—think of the drawn-out legal battles over addictive opioids or the decades it took to force Big Tobacco to be transparent about the health risks of smoking.

With CBD, the stakes revolve around consumer well-being and the ethical stewardship of a novel but promising domain of natural health solutions. Advocates of corporate social responsibility argue that if businesses genuinely care about the public, they must invest in robust scientific research and advertise responsibly. Kushly’s approach, as alleged in the complaint, runs counter to that ethos. Instead of disclaiming uncertainty or waiting for robust clinical trials, they allegedly leveraged people’s hopes and fears about serious diseases to sell more product.

Why does this matter for the average consumer? First, because public health rests on reliable information. When companies saturate the market with hype and misinformation, it becomes exceedingly difficult for everyday people—especially those with limited resources—to separate fact from fiction. Second, because the greater power corporations hold in shaping public discourse, the more they can overshadow genuine science and muzzle the voices that attempt to highlight the need for caution. If we are to encourage genuine innovation and ethical business practices, the regulatory environment must not only punish wrongdoing but also champion transparency and accountability. Yet, the pattern seen in Kushly’s case suggests we are still far from that ideal.

The Human Toll on Workers and Communities

Corporate misconduct in the form of false or overblown marketing claims can ripple outward, touching not only consumers but also the workers employed by these companies and the local communities in which they operate. During a brand’s rapid expansion—fueled by a spike in product sales—new jobs may appear: marketing specialists, warehouse staff, social-media managers, and so on. Workers can find themselves spending their days promoting products with unverified claims. In the short term, they have steady wages. But the looming threat of regulatory action often hangs over such operations. Should the FTC or another agency intervene, these jobs can disappear virtually overnight, leaving employees in precarious positions and local economies depleted of a once-promising employer.

Moreover, if the allegations are especially damaging or widely publicized, a scandal can poison the well for other businesses in the region or within the broader CBD sector. Reputable companies that do invest in scientific research and abide by regulatory guidance may find themselves tarred by association, as consumer trust plummets across the entire category. This phenomenon has been observed historically in many industries where one high-profile scandal clouds the reputation of all. In pharmaceutical manufacturing, for instance, a single contamination crisis can shake public faith in legitimate medical treatments. Similarly, in technology, a major data breach can trigger heightened skepticism about all tech platforms, not just the offending entity.

For local communities, the stakes can be even more tangible. If the offending company sponsored civic projects, philanthropic efforts, or local events, a collapse or abrupt shutdown can leave those programs in limbo. The intangible harm—disillusionment, economic uncertainty, and a deepening of cynicism toward corporate accountability—should not be overlooked. Local workers lose opportunities, and the community at large may be left reeling, especially if they believed that the enterprise’s growth was a sign of hopeful economic development.

Lastly, if Kushly’s alleged misconduct caused people to neglect proven treatments in favor of unsubstantiated CBD remedies, the hidden cost in public health terms could be severe. Chronic pain patients who believed they had found a cure might grow discouraged and suffer worsening conditions. Patients with diseases like cancer or Parkinson’s may miss out on timely interventions. Such scenarios underscore that what appears on the surface to be a marketing dispute can, in fact, carry life-altering consequences. These possible ripple effects highlight that corporate accountability is not just about dollars and fines but also about safeguarding human lives, local economies, and a collective sense of trust in the systems meant to protect us.

Global Trends in Corporate Accountability

The issues highlighted by the Kushly case mirror global trends. Around the world, industries ranging from tobacco and alcohol to infant formula and pesticides have come under fire for misleading or unethical practices. Frequently, such corporate strategies hinge on exploiting minimal regulatory oversight, sowing doubt about valid scientific critiques, and marketing aggressively to vulnerable populations.

In advanced economies, there is a push and pull between calls for stronger consumer protections and the persistent lobbying efforts of industries that prefer less oversight. Within developing markets, the tension can be even more noticeable, as regulatory frameworks are often in their infancy. These markets can become testing grounds for predatory corporate behavior, with local populations left at the mercy of marketing claims that no government agency has the resources to fully vet.

An interesting development in recent years is the rise of cross-border regulatory collaborations, spurred by recognition that deceptive advertising, especially online, respects no national boundaries. For example, the International Consumer Protection Enforcement Network (ICPEN) brings together consumer-protection authorities from around the globe to tackle cross-border aspects of fraudulent claims. Whether this collaborative approach can curb the surge of misinformation around unproven health solutions remains to be seen, but at least it suggests a growing global awareness of the problem.

Simultaneously, consumer advocacy groups, nonprofits, and online communities are stepping up efforts to fact-check corporate claims, publish accessible guides, and mount legal challenges. Organized boycotts, social media exposés, and grassroots pressure can, in some cases, force corporations to be more transparent or revisit their marketing strategies. However, the structural barriers remain steep. Without substantive legal or economic consequences that outstrip the profits from deception, unscrupulous companies often return to the same tactics under a slightly different brand or veneer.

Pathways for Reform and Consumer Advocacy

In confronting alleged corporate misconduct like that outlined against Kushly, it is easy to become cynical. But there are viable pathways to reform:

1. Strengthening Regulatory Mechanisms
   Governments can increase funding and authority for agencies like the FTC and the FDA so they can proactively police emerging markets, rather than reacting months or years later. Stricter guidelines, clear definitions, and swift penalties create an environment where corporations cannot simply gamble on minimal oversight.
2. Incentivizing Transparency
   Corporations that invest in genuine clinical research, publish findings, and follow ethical marketing standards should be recognized, possibly through a system of certifications or a more robust labeling scheme. Consumers would then have a clearer way to distinguish between ethically marketed and dubiously marketed products.
3. Enhanced Penalties
   If fines are consistently lower than potential profits, unscrupulous behavior becomes a rational business decision. Legislators could adjust penalty structures to ensure that corporations pay a sum proportionate to their sales, thereby discouraging fraudulent claims.
4. Consumer Education
   Advocacy groups, public-health organizations, and educators can play a pivotal role in teaching consumers to critically evaluate health claims. Simple guidelines—like looking for peer-reviewed studies, being wary of too-good-to-be-true promises, and seeking professional medical advice—can help individuals navigate an increasingly crowded and confusing marketplace.
5. Empowering Whistleblowers
   Employees within these organizations often have firsthand knowledge of dubious marketing tactics. Laws that protect and even reward whistleblowers could unearth misconduct sooner and deter companies from engaging in such practices in the first place.
6. Legal Channels Beyond Consumer Protection Agencies
   Class-action lawsuits and state-level consumer protection acts can supplement the work of federal agencies. By employing broader legal strategies, individuals harmed by false claims can seek redress more effectively, particularly when those claims lead to health complications or financial losses.
7. Global Cooperation
   Whether it is an international coalition or bilateral agreements, global data sharing and regulatory alignment help prevent corporations from simply shifting operations to jurisdictions with weaker oversight. For industries like CBD, which is widely sold online, global cooperation is crucial.

Ultimately, the goal is a rebalanced dynamic where genuine innovation thrives, backed by scientific validation, and unscrupulous profiteering is curbed. For that to happen, all stakeholders—consumers, researchers, ethical businesses, regulators, and legislators—must push for an environment where corporate accountability is not merely a buzzword but a tangible, enforceable principle.

The FTC did a press release about this act of corporate misconduct: https://www.ftc.gov/news-events/news/press-releases/2022/08/federal-trade-commission-returning-almost-21000-consumers-nationwide-who-bought-deceptively-marketed